Florida Doctors ~ So Far

florida

 

The doctors listed here have been recommended to Cushing’s Help by other patients as being helpful to them.  These physicians are familiar with the symptoms and treatment of Cushing’s Disease (pituitary) and Cushing’s Syndrome. Your primary care physician may be able to order very basic screening tests. Some of these doctors may require a referral and/or an abnormal test result prior to scheduling an appointment.

Cushing’s Help does not endorse any particular physician. Choosing a particular physician and substantiating his/her expertise is the responsibility of the individual patient.

To recommend your own doctor for this list, please fill out this form.

These doctors are also available on this map.  Please add yourself and/or your doctor.

This list is a continuing resource as new doctors are added, edited OR removed.

 

Florida

Jacksonville

Dr. Eric Sauvageau 

Specialty: Endovascular Neurosurgeon

Location: 800 Prudential Drive – Suite 1100
Jacksonville, FL

Phone: 904-388-6518

Website: http://www.baptistjax.com/doctors/endovascular-neurosurgeon/dr-eric-sauvageau-md

Patient Comment: I went to him for my IPSS procedure. I was VERY impressed by the care that I received. Dr. Sauvageau is Top-Notch! He answered all of my questions & made me feel more comfortable about the IPSS. Very caring. He made a REALLY scary test (that I had cried about many times) EASY PEASY. In fact, everyone at the hospital was super nice! I went to him based on the reviews of 2 other Cushies . He is highly experienced in the procedure and used to do IPSS tests at OSU. I had no pain afterwards and I could barely find where they went in.


 

More coming soon!

Rare Disease Week, 2014

rare-disease-2014

You are invited to join RDLA and 200 rare disease advocates in Washington, DC for Rare Disease Day (Week), February 25 – 28, 2013.  Below is an overview of the events, registration will be coming soon.

Tuesday, February 25th:
8:15 am – 4:30 pm Legislative Conference 
National Press Club, 529 14th Street NW, Washington, DC

5:30 pm – 9:30 pm 4th Annual Rare Disease Day Documentary Screening & Cocktail Reception
Carnegie Institution of Science, 1530 P Street Northwest, Washington DC

Wednesday, February 26th:
7:00am -8:30 am Lobby Training Breakfast
Top of the Hill, Reserve Officers Association, One Constitution Avenue, NE, Washington DC

9:00 am – 5 pm Capitol Hill Meetings with Members of Congress & Congressional Staff

Thursday, February 27th: 
9:00 am – 5 pm State Delegation Hill Meetings (Optional) Advocates drop by Congressional Offices and attend meetings on behalf of advocates who are too sick or unable to come to DC

TBD, Rare Disease Congressional Caucus Briefing

Friday, February 28th:
RDD@NIH Rare Disease Day at the National Institutes of Health – 2014 event information & registration coming soon

All events are free and open to the public, registration coming soon.

Hotel Room Block: Dupont Circle, on the Red Metro line:
Embassy Row Hotel, 2015 Massachusetts Ave, NW, Washington DC
$149/night single $169/night double + 14% DC Tax    Click Here to book your hotel ! or Call (202) 939-4208 & ask for the EveryLife Foundation Room Block
Complimentary internet in guest rooms, Complimentary breakfast
There are a limited number of rooms available at the discounted rate.  Discounted rates expire on Monday, February 3rd.

Click Here to watch the video presentations from last year’s Legislative Conference 

If you can’t join us in DC, please stay tuned for ways to share your personal story with Congress. 

Brigham & Womens Hospital’s Pituitary Day 2014

BWH_Pit_Day

In partnership with the Brain Science Foundation, the Brigham and Women’s Hospital Pituitary Neuroendocrine Center is pleased to present

Pituitary Day 2014

Saturday, March 29, 2013
8 AM – 5 PM
Bornstein Amphitheater
at Brigham & Women’s Hospital
75 Francis Street
Boston, MA

This conference is intended to unite patients, caregivers, family and friends with leading clinicians, researchers, nurses, and other experts to discuss the latest in pituitary diagnosis and treatment. All patients, caregivers, family and friends are welcome!

For more information, please visit brainsciencefoundation.org or call Sarah Donnelly at 781-239-2903.

Corcept Therapeutics Announces Partnership With Idis for Global Access to Korlym(R)

PRINCETON, NJ and MENLO PARK, CA, Jul 24, 2013 (Marketwired via COMTEX) — Corcept Therapeutics Incorporated CORT  announced today that Korlym(R) (mifepristone) 300 mg Tablets is available to patients outside of the United States through an Idis Access Program.

Idis Access Programs enable patients around the world to be prescribed investigational or approved drugs prior to their commercial launch in that country through a regulatory-compliant and ethical channel on a named-patient basis. Corcept, a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, has been offering Korlym in the United States since April 2012 as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing’s syndrome in adult patients who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

“We are pleased to partner with Idis so that physicians outside the United States can prescribe Korlym,” said Steven Lo, Corcept’s Vice President of Commercial Operations. “We are dedicated to meeting the needs of patients worldwide. Our partnership with Idis will help us make sure that every Cushing’s syndrome patient who could benefit from Korlym will have access to the medicine.”

Charles Simmons, President of Established Brands at Idis said of the partnership, “We are very excited to work with Corcept to provide patients around the world with access to this important treatment. Patients are at the heart of what we do at Idis and providing access to an important medicine like Korlym, creating a bridge to treatment irrespective of the number of patients involved, is one of the ways we do it”.

Licensed healthcare professionals outside the United States with patients who might benefit from Korlym should contact Idis directly:

Idis UK & Eire Enquiries Tel: +44 (0) 1932 824 100 Fax: +44 (0) 1932 824 300 Email: uk@idispharma.com

Idis Rest of the World Enquiries Tel: +44 (0) 1932 824 123 Fax: +44 (0) 1932 824 323 Email: internationalsales@idispharma.com

About Cushings Syndrome Endogenous Cushing’s syndrome is caused by prolonged exposure of the body’s tissues to high levels of the hormone cortisol and is generated by tumors that produce cortisol or ACTH. Cushing’s syndrome is an orphan indication that most commonly affects adults aged 20 to 50. Symptoms vary, but most people have one or more of the following manifestations: high blood sugar, diabetes, high blood pressure, upper body obesity, rounded face, increased fat around the neck, thinning arms and legs, severe fatigue and weak muscles. Irritability, anxiety, cognitive disturbances and depression are also common. Cushing’s syndrome can affect every organ system in the body and can be fatal if not treated effectively.

About Corcept Therapeutics Incorporated Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. Korlym, a first generation GR-II antagonist, is the company’s first FDA-approved medication. Corcept has a phase 3 trial underway for mifepristone for treatment of the psychotic features of psychotic depression and a portfolio of selective GR-II antagonists that block the effects of cortisol but not progesterone. It owns extensive intellectual property covering the use of GR-II antagonists, including mifepristone, in the treatment of a wide variety of metabolic and psychiatric disorders. It also holds composition of matter patents for its selective GR-II antagonists. For more information about Corcept please visit: http://www.corcept.com

About Idis Idis has 25 years experience partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987, Idis has developed and managed access to thousands of medicines from every therapeutic category, impacting the lives of hundreds of thousands of patients in countries around the world.

Idis leverages decades of experience, regulatory insight, and a thorough understanding of local and global requirements to create access to medicines at every stage of a product’s lifecycle from pre-approval to market exit, and in times of unexpected production shortages.

The company’s European headquarters are located in Weybridge, United Kingdom, and North American headquarters are located in Princeton, NJ.

For more information about Idis please visit http://www.idispharma.com.

From Marketwatch

Approach to testing growth hormone (GH) secretion in obese subjects.

Source

Faculty of Medicine, University of Belgrade, Department of Neuroendocrinology, Clinical Center Serbia, Dr Subotic 13, 11000 Belgrade, Serbia. popver@eunet.rs

Abstract

Identification of adults with GH deficiency (GHD) is challenging because clinical features of adult GHD are not distinctive and because clinical suspicion must be confirmed by biochemical tests.

Adults are selected for testing for adult GHD if they have a high pretest probability of GHD, ie, if they have hypothalamic-pituitary disease, if they have received cranial irradiation or central nervous system tumor treatment, or if they survived traumatic brain injury or subarachnoid hemorrhage.

Testing should only be carried out if a decision has already been made that if deficiency is found it will be treated. There are many pharmacological GH stimulation tests for the diagnosis of GHD; however, none fulfill the requirements for an ideal test having high discriminatory power; being reproducible, safe, convenient, and economical; and not being dependent on confounding factors such as age, gender, nutritional status, and in particular obesity.

In obesity, GH secretion is reduced, GH clearance is enhanced, and stimulated GH secretion is reduced, causing a false-positive result. This functional hyposomatotropism in obesity is fully reversed by weight loss. In conclusion, GH stimulation tests should be avoided in obese subjects with very low pretest probability.

PMID:
23650336
[PubMed – in process]

J Clin Endocrinol Metab. 2013 May;98(5):1789-96. doi: 10.1210/jc.2013-1099.

From http://www.ncbi.nlm.nih.gov/pubmed/23650336

%d bloggers like this: